Phase 1 progress for Debio 1143
December 2015


LAUSANNE, Switzerland—Debiopharm International SA, part of Debiopharm Group, recently announced several instances of clinical progress for the SMAC mimetic Debio 1143, an oral small-molecule inhibitor of inhibitor apoptosis proteins. Recommended dose was reached in two Phase 2 studies, and in a Phase 1/2 trial in combination with chemoradiotherapy in squamous cell carcinoma of the head and neck, Debio 1143 showed a favorable safety profile. Recommended dose was determined with a good tolerability profile in an indication screening study in combination with carboplatin and paclitaxel in patients with advanced solid malignancies, and promising signs of efficacy were also seen in ovarian cancer patients. Jean-Maurice Dumont, vice president of clinical research and development for Debiopharm International, remarked that “We have reached an important step in the development of Debio 1143. Its chemo/radiosensitization property will now be further investigated in Phase 2 trials.”

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.